Trials / Completed
CompletedNCT03820414
Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Antigen Dose-Escalation and Adjuvant Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Curevo Inc · Industry
- Sex
- All
- Age
- 18 Years – 49 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this clinical trial is to evaluate the safety, tolerability, and immunogenicity of vaccine candidate CRV-101, investigational vaccine in healthy adult subjects in the United States.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CRV 101 | (Different formulations) |
| BIOLOGICAL | Placebo | 2 doses administered IM in deltoid region of non-dominant arm |
Timeline
- Start date
- 2019-01-03
- Primary completion
- 2020-04-04
- Completion
- 2020-04-30
- First posted
- 2019-01-29
- Last updated
- 2021-02-11
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03820414. Inclusion in this directory is not an endorsement.